AMENDMENTS TO THE CLAIMS

- 2. (Currently amended) A method of inhibiting an antigen-specific response of an immune system a T cell to subsequent presentation of said antigen, comprising administering to said immune system T cell an effective amount of exogenous interleukin-10 and said antigen.
 - 3. (Currently amended) The method of Claim 2:
- a) wherein said <u>immune T cell</u> response is mediated by a macrophage, APC, langerhans cell, or dendritic cell;
- b) further inhibiting proliferative response of CD4+ host-reactive T cell clones; or
 - c) wherein said inhibiting persists for at least about 21 days.
- 4. (Original) The method of Claim 2, wherein said effective amount is sufficient to decrease responder T cell activation.
- 5. (Currently amended) The method of Claim 4, further comprising reduced <u>T cell-stimulatory</u> capacity of peripheral blood mononuclear cells, dendritic cells, monocytes, and/or normal B cells.
- 15. (Previously amended) A method of suppressing an immune response of a T cell response to an antigen, comprising administering to said \underline{T} cell a combination of:
 - a) IL-10; and
 - b) either said antigen or anti-CD3 antibodies.
- 16. (Original) The method of Claim 15, wherein said antigen is alloantigen or self antigen.

- 17. (Original) The method of Claim 16, wherein said antigen is restricted by MHC molecules.
 - 18. (Original) The method of Claim 15, performed in vivo.
- 19. (Currently amended) The method of Claim 15, which further comprising suppressing a T cell response to subsequent stimulation to [said T cell with] said antigen.
- 20. (Currently amended) The method of Claim 19, wherein said response to subsequent stimulation accompanies tissue transplantation.
- 21. (Original) The method of Claim 20, wherein said tissue is an organ or bone marrow.
- 22. (Original) The method of Claim 20, wherein said T cell is from the recipient of said tissue transplantation.
- 23. (Original) The method of Claim 15, wherein said response accompanies tissue transplantation and:
 - a) said administering is prior to said tissue transplantation;
 - b) said T cell is introduced to the recipient of said tissue transplantation; or
 - c) IL-10 is administered to the tissue to be transplanted before said transplantation.
- 24. (Original) The method of Claim 16, wherein said antigen causes an autoimmune disease.

- 25. (Currently amended) A method of suppressing a subsequent response inof a T cell to an antigen, comprising administering to an immune system a T cell comprising said cell with a combination of:
 - a) exogenous IL-10; and
 - b) either antigen or anti-CD3 antibodies.
- 26. (Original) The method of Claim 25, wherein said IL-10 is administered for at least about 7 days.
- 27. (Currently amended) A method of inducing in T cell anergy to an MHC antigen, comprising administering to a <u>T cell</u> precursor to said <u>T cell</u>;
 - a) exogenous IL-10 and said antigen; or
 - b) exogenous IL-10 and an anti-CD3.